Senores Pharmaceuticals Limited has informed the Exchange regarding a Media release dated May 15, 2025 in relation to the Audited Standalone and Consolidated financial results of the Company for the quarter and financial year ended March 31, 2025.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts less than Nifty Microcap 250 and 8.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Senores Pharmaceuticals Limited announced its audited consolidated financial results for Q4 FY25 and the full financial year ended March 31, 2025, sharing an updated media release that supersedes an earlier one filed the same day. For FY25, total income surged 91% year-on-year to Rs. 410 crore, EBITDA jumped 145% to Rs. 102 crore, and profit before tax (PBT) grew 183% to Rs. 71 crore. EBITDA margin expanded sharply from 19.4% in FY24 to 24.8% in FY25, supported by regulated market revenue growing 69% to Rs. 244.8 crore and emerging markets revenue nearly tripling with 174% growth to Rs. 121.2 crore. The company strengthened its pipeline by acquiring 14 ANDAs from Dr. Reddy's and 1 ANDA from Breckenridge, while expanding its CDMO/CMO segment with 69 products in the pipeline. Management flagged US tariff uncertainties as a risk to monitor, but highlighted the company's USFDA-approved Atlanta facility as a hedge against these headwinds.
Strong topline growth, tripled profits, and expanded margins should boost investor confidence and support a positive market reaction. The US tariff risk and dependence on regulated market execution remain the key things for shareholders to track going forward.